TY  - CHAP
M1  - Book, Section
TI  - Chapter 28. Invasive Fungal Infections
A1  - Slain, Douglas
A2  - Sutton, S. Scott
PY  - 2011
T2  - McGraw-Hill's NAPLEX® Review Guide
AB  - Invasive  fungal  infections  are  associated  with  significant  morbidity  and  mortality  and  occur  most  frequently  in  immunocompromised  patients.1Candida  species  represent  the  fourth  most  common  cause  of  bloodstream  infections  in  hospitalized  patients.2  Over  the  past  decade,  the  field  of  clinical  mycology  has  changed  dramatically  and  there  has  been  a  doubling  of  licensed  medications  available  for  systemic  fungal  infections.  Advances  in  medical  technology,  including  organ  and  bone  marrow  transplantation,  cytotoxic  chemotherapy,  the  widespread  use  of  indwelling  IV  catheters,  and  the  increased  use  of  broad-spectrum  antibiotics  have  contributed  to  the  increase  of  fungal  infections.  
SN  - 
PB  - The McGraw-Hill Companies
CY  - New York, NY
Y2  - 2024/04/20
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=7252384
ER  -